Management of refractory autoimmune hepatitis with rituximab: a case series
Rituximab appears safe, and also effective in some patients with autoimmune hepatitis who have been refractory to standard of care. The dose reduction for other disease modifying agents makes rituximab an attractive option for this difficult to treat subset of patients.
Authors
- Nicholas Batt (ORCID: https://orcid.org/0000-0002-0845-3341)
- Amanda Nicoll (ORCID: https://orcid.org/0000-0002-1855-2757)
- Geoffrey Haar (ORCID: https://orcid.org/0000-0003-2275-7541)
- Stephen Bloom (ORCID: https://orcid.org/0000-0003-1170-6757)
Institutions
- Eastern Health (AU)
- Austin Health (AU)
Publication Details
- Journal
- Journal of Medical Case Reports
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1186/s13256-025-05595-3
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00